Antibodies that specifically bind human CD96
US11680098B2 · kind B2 · utility
0Cited by
2References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 31, 2020 |
| Grant date | Jun 20, 2023 |
| Priority date | — |
| Expiry date | May 1, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The instant disclosure provides antibodies that specifically bind to CD96 (e.g., human CD96) and antagonize CD96 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.